Elanix Signs Supply and Manufacturing Agreements with Sincopharm and Tec-Pharma

Elanix Biotechnologies AG (FSE:ELN), a developer of tissue regeneration products, announced today the signing of supply agreements with two Swiss companies, Sincopharm SA and Tec-Pharma SA. The agreements will assure manufacturing sustainability at high quality and supply reliability of two commercially available medical cosmetic products, to alleviate gynecological and dermatological conditions, obtained from the recent acquisition of Repair-A SA.
Elanix now has complete control of the formulation, production and
commercialization worldwide for the two progenitor cell-based products
GynRepair, a treatment for vulvodynia and RepAir-A, a dermatological
used to rejuvenate the skin following damage. Elanix anticipates
significant sales growth for these products in the next 12 months
through combination of direct and distributor sales initially in
Switzerland and Europe.
“These agreements allow Elanix to ensure our customers continue to have
access to these innovative products. There is significant demand for
effective and proven medical cosmetics, and we are now uniquely placed
to access these growing markets,” Tomas Svoboda, CEO, Elanix
Biotechnologies AG stated. “Our OTC division, headed by Bruno Tenaille,
will now begin to roll out a comprehensive marketing and sales strategy
to reach as many existing and new customers as possible.”
Both based in Switzerland, Sincopharm SA is dedicated to
development and manufacturing of cosmetic formulations. It was
established in 1989 by two pharmacists Pierre and Christian Aubort. Tec-Pharma
SA is a cosmetic developer and manufacturer of biological actives
for a range of applications for both human and veterinary use.
Elanix Biotechnologies (Frankfurt: ELN) develops and
commercializes tissue regeneration products for acute wound care,
dermatological and gynecological applications, and provides services in
cell technologies. The company was founded in 2013 as a spin-out from
the University Hospital of Lausanne (CHUV), Switzerland, to
commercialize a patented progenitor cell technology. Progenitor cells
are fully differentiated yet immunologically neutral cells that are very
potent inducers of tissue growth and healing. Elanix owns GMP certified
Master and Working cell banks with vast quantities of cells of different
cell types.
The Company is headquartered in Nyon, Switzerland with offices in
Potsdam and listed on the Frankfurt stock exchange under the symbol ELN.
For more information and updates, visit www.elanix-biotechnologies.com.
Disclaimer / Forward-looking statements:
This publication may contain certain forward-looking statements
concerning the Company and its business. Such statements involve certain
risks, uncertainties and other factors which could cause the actual
results, financial condition, performance or achievements of the Company
to be materially different from those expressed or implied by such
statements. Readers should therefore not place undue reliance on these
statements, particularly not in connection with any contract or
investment decision. The Company disclaims any obligation to update
these forward-looking statements.